CP

Caligan Partners Portfolio holdings

AUM $515M
This Quarter Return
+16.59%
1 Year Return
+70.09%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$479M
AUM Growth
+$479M
Cap. Flow
+$49.2M
Cap. Flow %
10.27%
Top 10 Hldgs %
91.9%
Holding
17
New
3
Increased
8
Reduced
–
Closed
1

Top Buys

1
MLYS icon
Mineralys Therapeutics
MLYS
$18.1M
2
RVMD icon
Revolution Medicines
RVMD
$16.4M
3
MRUS icon
Merus
MRUS
$5.13M
4
ABVX
Abivax
ABVX
$3.23M
5
YMAB icon
Y-mAbs Therapeutics
YMAB
$2.55M

Top Sells

1
ENTA icon
Enanta Pharmaceuticals
ENTA
$1.06M

Sector Composition

1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Shares
Change % 		Capital Flow
LQDA icon
1
Liquidia Corp
LQDA
$2.38B
$120M 24.99% 8,118,592 – –
VRNA
2
Verona Pharma
VRNA
$9.16B
$91.2M 19.04% 1,436,878 – –
EXEL icon
3
Exelixis
EXEL
$10.1B
$56.3M 11.75% 1,525,730 – –
MLYS icon
4
Mineralys Therapeutics
MLYS
$1.03B
$34.1M 7.12% 2,149,667 +1,138,512 +113% +$18.1M
EOLS icon
5
Evolus
EOLS
$494M
$32.9M 6.86% 2,731,154 +38,766 +1% +$466K
SAGE
6
DELISTED
Sage Therapeutics
SAGE
$24.3M 5.06% 3,052,538 – –
BCRX icon
7
BioCryst Pharmaceuticals
BCRX
$1.74B
$23.3M 4.86% 3,107,669 +111,737 +4% +$838K
ANIK icon
8
Anika Therapeutics
ANIK
$135M
$21.6M 4.5% 1,435,130 – –
AGIO icon
9
Agios Pharmaceuticals
AGIO
$2.19B
$20.5M 4.29% 701,280 +75,000 +12% +$2.2M
RVMD icon
10
Revolution Medicines
RVMD
$7.1B
$16.4M 3.43% +465,000 New +$16.4M
MRUS icon
11
Merus
MRUS
$4.98B
$15.9M 3.31% 376,954 +121,954 +48% +$5.13M
YMAB icon
12
Y-mAbs Therapeutics
YMAB
$388M
$10.4M 2.17% 2,342,609 +574,627 +33% +$2.55M
ABVX
13
Abivax
ABVX
$6.12B
$7.93M 1.66% 1,269,119 +516,952 +69% +$3.23M
VRCA icon
14
Verrica Pharmaceuticals
VRCA
$52.8M
$3.98M 0.83% 8,992,954 +1,563,267 +21% +$691K
RZLT icon
15
Rezolute
RZLT
$619M
$410K 0.09% +141,309 New +$410K
TYRA icon
16
Tyra Biosciences
TYRA
$675M
$233K 0.05% +25,000 New +$233K
ENTA icon
17
Enanta Pharmaceuticals
ENTA
$180M
– – -184,826 Closed -$1.06M